Celladon Will Become Rare Disease-Focused Eiger
This article was originally published in Scrip
Executive Summary
Celladon Corp. will be acquired in a reverse merger with Eiger BioPharmaceuticals Inc., which means Celladon will not have to liquidate its assets to return cash to shareholders following discontinuation of development for the genetically-targeted enzyme replacement therapy Mydicar for heart failure.
You may also be interested in...
Eiger Shifts Focus After Phase II Failure In PAH
Finding no improvement with ubenimex in PAH, Eiger ends development but continues with the drug in lymphedema, plus hepatitis D and post-bariatric hypoglycemia candidates.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.